TRIPLE THERAPY WITH BUDESONIDE/GLYCOPYRROLATE/FORMOTEROL FUMARATE WITH CO-SUSPENSION DELIVERY TECHNOLOGY VERSUS DUAL THERAPIES IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE (KRONOS): A DOUBLE-BLIND, PARALLEL-GROUP, MULTICENTRE, PHASE 3 RANDOMISED CONTROLLED

Gary T Ferguson, Klaus F Rabe, Fernando J Martinez, Leonardo M Fabbri, Chen Wang, Masakazu Ichinose, Eric Bourne, Shaila Ballal, Patrick Darken, Kiernan DeAngelis, Magnus Aurivillius, Paul Dorinsky, Colin Reisner

The research aimed to evaluate the potential benefits of triple therapy in symptomatic COPD patients who had not responded adequately to dual therapies. The study recruited patients aged 40-80 years with a history of COPD and assessed various clinical endpoints over a 24-week period. Results indicated significant differences in exacerbation rates and quality of life measures between the treatment groups, highlighting the importance of therapy choice in managing COPD.